INVITED SPEAKER
MICHAEL HOFMAN
PET Modality Lead, Molecular Imaging and Therapeutic
Nuclear Medicine, Cancer Imaging
Director, Prostate Cancer Theranostics and Imaging
Centre of Excellence (ProsTIC)
Sir Peter MacCallum Department of Oncology,
The University of Melbourne